Matti Pokela
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Matti Pokela has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Toni Pihlaja
Department of Vascular Surgery, University of Oulu and Oulu University Hospital, Oulu, Finland; Medical Research Center Oulu, University of Oulu, Oulu, Finland
3 shared publications - Harri Hakovirta
Department of Vascular Surgery, Turku University Hospital, Turku, Finland; University of Turku, Turku, Finland
2 shared publications - Jaakko Viljamaa
Department of Vascular Surgery, Turku University Hospital, Turku, Finland; University of Turku, Turku, Finland
2 shared publications - Karoliina Halmesmäki
Department of Vascular Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
2 shared publications Maarit Venermo
Department of Vascular Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
2 shared publications- Pasi Ohtonen
Research Service Unit, Oulu University Hospital, Oulu, Finland; Translational Medicine Research Unit, University of Oulu, Oulu, Finland
2 shared publications
Latest Publications
- Open Access
- 22 January 2026
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 71 (6) , 1071-1079
Early Outcomes of a Randomised Controlled Trial Comparing Concomitant with Staged Tributary Treatment as an Adjunct to Endovenous Laser Ablation of the Saphenous Trunk: The FinnTrunk Study
- 22 January 2026
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 71 (6) , 1071-1079
Open AccessEarly Outcomes of a Randomised Controlled Trial Comparing Concomitant with Staged Tributary Treatment as an Adjunct to Endovenous Laser Ablation of the Saphenous Trunk: The FinnTrunk Study
- Open Access
- 1 January 2025
- Published by Wiley in Journal of Cardiac Surgery
- Vol. 2025 (1)
Surgically Treated Infective Endocarditis in Intravenous Drug Users: A Retrospective Analysis of Patient Characteristics and Survival Between 1998 and 2018
Background: Infective endocarditis (IE) is an increasingly more common disease with poor prognosis. Recently, a few single‐center studies about IE patient characteristics and surgical outcomes have been published from the capital area in Southern Finland. Our aim was to provide the first descriptive analysis of surgically treated IE patients in the northernmost university hospital in Finland. Methods: All IE patients who had their first operation due to IE between 1998 and 2018 were retrospectively collected from the hospital discharge register, and their electronic patient records were analyzed. Follow‐up for survival lasted to the end of 2021. The primary endpoint in survival analyses was all‐cause mortality. Results: A total of 128 novel IE cases were operated between 1998–2018. Twenty (15.6%) of the patients had a history of intravenous drug use. The median (1st–3rd quartile) follow‐up after surgery was 76 (26–139) months. A total of 49 (45.5%) of the nonusers and 11 (55.0%) of the drug users died during the follow‐up period. The 90‐day mortality was significantly higher among nonusers compared with patients using intravenous drugs (18.5% vs. 0.0%, p = 0.036). Staphylococcus aureus was the most common underlying pathogen (42% of all cases) and posed nearly a 2‐fold risk for overall mortality even after adjusting for confounding: hazard ratio: 1.781 (95% confidence interval: 1.054–3.008, p = 0.031). Conclusions: IE is a rare disease with poor outcomes. S. aureus is the most common underlying pathogen and a major risk factor for mortality in patients not using intravenous drugs.
- 1 January 2025
- Published by Wiley in Journal of Cardiac Surgery
- Vol. 2025 (1)
Open AccessSurgically Treated Infective Endocarditis in Intravenous Drug Users: A Retrospective Analysis of Patient Characteristics and Survival Between 1998 and 2018
Background: Infective endocarditis (IE) is an increasingly more common disease with poor prognosis. Recently, a few single‐center studies about IE patient characteristics and surgical outcomes have been published from the capital area in Southern Finland. Our aim was to provide the first descriptive analysis of surgically treated IE patients in the northernmost university hospital in Finland. Methods: All IE patients who had their first operation due to IE between 1998 and 2018 were retrospectively collected from the hospital discharge register, and their electronic patient records were analyzed. Follow‐up for survival lasted to the end of 2021. The primary endpoint in survival analyses was all‐cause mortality. Results: A total of 128 novel IE cases were operated between 1998–2018. Twenty (15.6%) of the patients had a history of intravenous drug use. The median (1st–3rd quartile) follow‐up after surgery was 76 (26–139) months. A total of 49 (45.5%) of the nonusers and 11 (55.0%) of the drug users died during the follow‐up period. The 90‐day mortality was significantly higher among nonusers compared with patients using intravenous drugs (18.5% vs. 0.0%, p = 0.036). Staphylococcus aureus was the most common underlying pathogen (42% of all cases) and posed nearly a 2‐fold risk for overall mortality even after adjusting for confounding: hazard ratio: 1.781 (95% confidence interval: 1.054–3.008, p = 0.031). Conclusions: IE is a rare disease with poor outcomes. S. aureus is the most common underlying pathogen and a major risk factor for mortality in patients not using intravenous drugs.
- 4 April 2024
- Published by SAGE Publications in The International Journal of Lower Extremity Wounds
- Vol. 25 (2) , 509-514
Sub-ulcer Foam Sclerotherapy in Patients with Venous Leg Ulcer, Analysis and Technical Aspects of 134 Consecutive Patients
Objective: For this retrospective study, we analyzed the sub-ulcer foam sclerotherapy technique in patients with venous leg ulcer (VLU). Methods: This study included 134 patients treated with sub-ulcer foam sclerotherapy at the Oulu University Hospital vascular outpatient clinic from January 2012 to December 2021. All included patients received sub-ulcer foam sclerotherapy as part of the treatment strategy for superficial venous insufficiency. Compression therapy and local wound care were organized for VLU treatment. A follow-up visit was scheduled for one month after the sub-ulcer foam sclerotherapy. Change in ulcer size, local (skin necrosis, infection) or systemic (deep vein thrombosis, pulmonary embolism) complications, and time to ulcer healing were monitored. The occurrence of major limb-related complications (amputation, surgical revision) was monitored for one year postoperatively. Results: One month after sub-ulcer treatment, ulcers were smaller or completely healed in 108 (81%) patients. Ulcer healing was completed in 123 (92%) patients at one year and 131 (98%) patients at two years. Complications were recorded in four (3%) patients, three (2%) who were diagnosed with erysipelas requiring antibiotic treatment and one (1%) patient diagnosed with local dermatitis. During the one-year follow-up, no major limb-related complications (surgical revisions or amputations) arose. Conclusions: Sub-ulcer foam sclerotherapy may be a feasible addition to superficial vein reflux elimination in patients with VLU and a low risk for complications.
- 4 April 2024
- Published by SAGE Publications in The International Journal of Lower Extremity Wounds
- Vol. 25 (2) , 509-514
Sub-ulcer Foam Sclerotherapy in Patients with Venous Leg Ulcer, Analysis and Technical Aspects of 134 Consecutive Patients
Objective: For this retrospective study, we analyzed the sub-ulcer foam sclerotherapy technique in patients with venous leg ulcer (VLU). Methods: This study included 134 patients treated with sub-ulcer foam sclerotherapy at the Oulu University Hospital vascular outpatient clinic from January 2012 to December 2021. All included patients received sub-ulcer foam sclerotherapy as part of the treatment strategy for superficial venous insufficiency. Compression therapy and local wound care were organized for VLU treatment. A follow-up visit was scheduled for one month after the sub-ulcer foam sclerotherapy. Change in ulcer size, local (skin necrosis, infection) or systemic (deep vein thrombosis, pulmonary embolism) complications, and time to ulcer healing were monitored. The occurrence of major limb-related complications (amputation, surgical revision) was monitored for one year postoperatively. Results: One month after sub-ulcer treatment, ulcers were smaller or completely healed in 108 (81%) patients. Ulcer healing was completed in 123 (92%) patients at one year and 131 (98%) patients at two years. Complications were recorded in four (3%) patients, three (2%) who were diagnosed with erysipelas requiring antibiotic treatment and one (1%) patient diagnosed with local dermatitis. During the one-year follow-up, no major limb-related complications (surgical revisions or amputations) arose. Conclusions: Sub-ulcer foam sclerotherapy may be a feasible addition to superficial vein reflux elimination in patients with VLU and a low risk for complications.